中华神经外科杂志
2025年 · 第41卷第06期
中华神经外科杂志
Glioma is a malignant primary brain tumor caused by the disorderly proliferation of neural stem cells or neural precursor cells driven by carcinogenic mutations[1]。 Glioma accounts for 80% of malignant primary brain tumors and is the most important cause of death[2]。 Among them, glioblastoma (GBM) is the most malignant glioma, and the median survival of patients<17 months[3,4]。 The standard treatment regimen for GBM is the maximum degree of safe resection and postoperative adjuvant chemoradiotherapy, but the effect of prolonging the survival of patients with standard treatment regimen has reached a bottleneck[5]。 Currently, tumor electric field therapy has been included in the standard treatment protocol for emerging GBM[1]。 However, the median overall survival of patients after tumor electric field therapy was only prolonged by less than 3 months[6]。 In conclusion, the treatment of glioma has not improved significantly in the past two decades[7]。 In view of the current status of glioma treatment, it is common practice internationally to recommend patients to participate in suitable clinical trials as far as possible to seek possible effective treatment options. Drug sensitivity (drug sensitivity) detection based on tumor organoids has been gradually emerging in recent years. It has the characteristics of high accuracy and strong predictability. At present, it has been successfully used to assist the formulation of tumor treatment schemes such as colorectal cancer and rectal cancer, which can provide an important basis for clinical trial drugs. In the Guidelines for Integrated Diagnosis and Treatment of Brain Glioma of China Anti-Cancer Association (2024 Edition) (https: / /cacaguidelines.cacakp.com/pdflist/detail? id =415), "Chemotherapy under the guidance of in vitro drug susceptibility tests such as organoid models can be considered as a selective reference for individualized treatment" has been added. However, organoid drug susceptibility detection has not been used in the treatment of glioma on a large scale. At present, the centers for organoid drug susceptibility testing of glioma are scattered, and no large-scale multicenter cohort study has been retrieved, which limits the potential benefits of glioma patients in organoid drug susceptibility testing. The Glioma Professional Committee of China Anti-Cancer Association, in conjunction with a number of basic research and clinical diagnosis and treatment teams of glioma in China, summarized the existing application of drug sensitivity detection of glioma organoids at home and abroad by comprehensively searching and reviewing the research literature related to glioma organoids, and jointly formulated the Expert Consensus on the Application of Organoid Drug Sensitivity Detection in Precision Treatment of Glioma (First Edition) in combination with the specific needs of glioma diagnosis and treatment in China. It is intended to improve the understanding of clinical experts and scientific researchers in the field of glioma in China on organoid-guided precision treatment, standardize the quality control of glioma organoids, and promote the application of glioma organoids in the field of precision medicine.
本期目次


